The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Deborah NejmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelIlana LivyatanDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, IsraelGarold FuksDepartment of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, IsraelNancy GavertDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelYaara ZwangDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelLeore T. GellerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelAviva Rotter-MaskowitzDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelRoi WeiserDivision of Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv, IsraelGiuseppe MallelDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelElinor GigiDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelArnon MeltserDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, IsraelGavin M. DouglasDepartment of Microbiology and Immunology, Dalhousie University, Halifax, NS, CanadaIris KamerInstitute of Oncology, Sheba Medical Center, Ramat Gan, IsraelVancheswaran GopalakrishnanDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USATali DadoshDepartment of Chemical Research Support, Weizmann Institute of Science, Rehovot, IsraelSmadar Levin‐ZaidmanDepartment of Chemical Research Support, Weizmann Institute of Science, Rehovot, IsraelSofia AvnetOrthopaedic Pathophysiology and Regenerative Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, ItalyTehila AtlanDepartment of Bioinformatics, Jerusalem College of Technology, Jerusalem, IsraelZachary A. CooperTranslational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD, USAReetakshi AroraDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAAlexandria P. CogdillDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAMd Abdul Wadud KhanDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAGabriel O OlogunDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAYuval BussiDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, IsraelAdina WeinbergerDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, IsraelMaya Lotan‐PompanDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, IsraelOfra GolaniDepartment of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, IsraelGili PerryCancer Research Center, Sheba Medical Center, Ramat Gan, IsraelMerav RokahDepartment of Thoracic Surgery, Sheba Medical Center, Ramat Gan, IsraelKeren Bahar‐ShanyCancer Research Center, Sheba Medical Center, Ramat Gan, IsraelElisa A. RozemanDepartment of Medical Oncology and Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, NetherlandsChristian U. BlankDepartment of Medical Oncology and Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, NetherlandsAnat RonaiPediatric Gastroenterology Institute, Rambam Medical Center, Haifa, IsraelRon ShaoulPediatric Gastroenterology Institute, Rambam Medical Center, Haifa, IsraelAmnon AmitDepartment of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa, IsraelTatiana DorfmanAmbulatory and Breast Surgery Service, Rambam Health Care Campus, Haifa, IsraelRan KremerDepartment of Thoracic Surgery, Rambam Health Care Campus, Haifa, IsraelZvi R. CohenDepartment of Neurosurgery, Sheba Medical Center, Ramat Gan, IsraelSagi HarnofDepartment of Neurosurgery, Rabin Medical Center, Beilinson Hospital, Petach Tikva, IsraelTali SiegalNeuro-Oncology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, IsraelEinav Yehuda‐ShnaidmanInstitute of Pathology, Megalab, Maccabi Healthcare Services, Rehovot, IsraelEinav Nili Gal‐YamBreast Oncology Institute, Sheba Medical Center, Ramat Gan, IsraelHagit ShapiraInstitute of Pathology, Megalab, Maccabi Healthcare Services, Rehovot, IsraelNicola BaldiniDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ItalyMorgan G. I. LangilleDepartment of Microbiology and Immunology, Dalhousie University, Halifax, NS, CanadaAlon Ben‐NunDepartment of Thoracic Surgery, Sheba Medical Center, Ramat Gan, IsraelBella KaufmanInstitute of Oncology, Sheba Medical Center, Ramat Gan, IsraelAviram NissanDepartment of Surgical Oncology (Surgery C), Sheba Medical Center, Ramat Gan, IsraelTalia GolanInstitute of Oncology, Sheba Medical Center, Ramat Gan, IsraelMaya DadianiCancer Research Center, Sheba Medical Center, Ramat Gan, IsraelKeren LevanonCancer Research Center, Sheba Medical Center, Ramat Gan, IsraelJair BarInstitute of Oncology, Sheba Medical Center, Ramat Gan, IsraelShlomit Yust‐KatzNeuro-Oncology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, IsraelIris BarshackDepartment of Pathology, Sheba Medical Center, Ramat Gan, IsraelDaniel S. PeeperDivision of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, NetherlandsDan J. RazDivision of Thoracic Surgery, City of Hope Medical Center, Duarte, CA, USAEran SegalDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, IsraelJennifer A. WargoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAJudith SandbankInstitute of Pathology, Megalab, Maccabi Healthcare Services, Rehovot, IsraelNoam ShentalDepartment of Mathematics and Computer Science, The Open University of Israel, Ra’anana, IsraelRavid StraussmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
2020en
ABI
Аннотация
Bacteria were first detected in human tumors more than 100 years ago, but the characterization of the tumor microbiome has remained challenging because of its low biomass. We undertook a comprehensive analysis of the tumor microbiome, studying 1526 tumors and their adjacent normal tissues across seven cancer types, including breast, lung, ovary, pancreas, melanoma, bone, and brain tumors. We found that each tumor type has a distinct microbiome composition and that breast cancer has a particularly rich and diverse microbiome. The intratumor bacteria are mostly intracellular and are present in both cancer and immune cells. We also noted correlations between intratumor bacteria or their predicted functions with tumor types and subtypes, patients' smoking status, and the response to immunotherapy.
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0